Evaluation of Insulin and Estradiol in Women with Polycystic Ovary Syndrome and its Relationship With BMI

 Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, which is characterized by ovulatory dysfunction and hyperandrogenism. This study was done to evaluate insulin and estradiol (E2) in women with PCOS and its relationship with Body mass index (BMI).

This case-control study included, 104 women with polycystic ovary syndrome as a case group and 100 women without polycystic ovary syndrome as a control group. Concentrations of insulin, glucose and E2 were measured in fasting blood samples.

Insulin level was 7.02 ± 3.29 in control group, 11.41 ± 3.84 in the case group. FBS level was 82.75 ± 7.18 in control group versus 84.03 ± 5.82 in case group. E2 level was 70.74 ± 53.03 in control group and 60.21 ± 40.58 in case group. The insulin resistance level was 1.45 ± 0.74 in the control group versus 2.37 ± 0.83 in case group. According to correlation analysis, the insulin variable had a significant positive association with BMI (p < 0.0001, r=.245), although no significant correlation was seen between E2 and BMI (p-value = 0.245, r=.092)

Present data showed that E2 levels were not different in PCOS and non-PCOS patients, but insulin levels in PCOS were significantly increased and PCOS women had significant insulin resistance which is dependent on BMI.